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Methods:
Single dose intravenous SVV-001 was investigated across 5 log-increment dose cohorts from 10 7 vp/kg to 10 11 vp/kg, in patients with carcinoid type cancers. Study endpoints included toxicity assessment, response assessment, evaluation of viral titers and clearance in blood, sputum, nasal swabs, urine, and stool, and neutralizing antibody development.
Results: 12 carcinoid patients in cohorts 1 to 4 had a 70% SD rate. Cohort 5, a 12 patient expansion cohort at 10 11 vp/kg showed promising antitumor activity including improvement in carcinoid syndrome symptoms, decline in 5HIAA and other serum markers, minor responses by CT scan, and an objective PET response (>50% decrease in SUV). Median PFS was 6.2 months (95% CI 3.6 to 21.1), median OS was 21.1 months (95% CI 8.9 to not reached).
There were no DLTs in any cohort. Side effects were in general mild and self limiting. Evidence of intratumoral viral replication was demonstrated with detection of delayed viral titers estimated at >1,000 the administered dose. Viral clearance was documented in all patients and correlated temporally with development of antiviral antibodies.
Conclusions:
A single IV dose of 10 11 vp/kg of SVV-001 is safe with predictable viral kinetics and shows promising activity against NE tumors. Phase II testing of this novel anticancer agent is warranted.
